Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#177 / 177 Total
PEPG - PepGen Inc - Stock Price Chart
TickerPEPG [NASD, RUT]
CompanyPepGen Inc
CountryUSA
IndustryBiotechnology
Market Cap453.78MEPS (ttm)-3.30
P/E-EPS this Y12.79%
Forward P/E-EPS next Y4.72%
PEG-EPS past 5Y-172.30%
P/S-EPS next 5Y-
P/B3.08EPS Q/Q-29.94%
Dividend-Sales Q/Q-
Insider Own16.17%Inst Own60.40%
Insider Trans95.56%Inst Trans-0.43%
Short Float1.66%EarningsMar 06/a
Analyst Recom1.00Target Price21.60
Avg Volume88.31K52W Range3.72 - 17.51
Apr-12-24 01:30PM Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More (Insider Monkey)
Mar-13-24 04:05PM PepGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-12-24 09:55AM Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-11-24 12:00PM PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-06-24 11:54PM PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 (InvestorPlace) -7.34%
04:01PM PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-29-24 03:02AM 14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +14.68%
Feb-20-24 08:00AM PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '24Buy10.642,557,59327,212,7909,179,273Feb 13 04:33 PM
McArthur James GPresident and CEONov 30 '23Buy4.171,6947,0561,694Dec 05 07:34 AM
McArthur James GPresident and CEOJun 08 '23Option Exercise2.712,3816,4532,381Jun 09 07:06 PM
McArthur James GPresident and CEOJun 08 '23Sale16.042,38138,1880Jun 09 07:06 PM
McArthur James GPresident and CEOJun 07 '23Option Exercise2.718,41922,8158,419Jun 08 05:23 PM
1⋯10⋯131415161718
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.